2019
Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension
Abraldes JG, Trebicka J, Chalasani N, D’Amico G, Rockey DC, Shah VH, Bosch J, Garcia‐Tsao G. Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension. Hepatology 2019, 69: 1287-1299. PMID: 30318607, PMCID: PMC11090176, DOI: 10.1002/hep.30314.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseasePortal pressurePortal hypertensionLiver diseaseCardiac output leadsCause of cirrhosisCirrhotic portal hypertensionChronic liver diseaseFatty liver diseasePortal venous inflowIntrahepatic vascular resistanceRisk of decompensationEarly clinical studiesCirrhosis decompensationSplanchnic vasodilationVascular resistancePharmacological therapyEtiological treatmentVenous inflowCirrhosis resultsSuch therapyClinical trialsBest therapyClinical studiesCirrhosis
2016
Prevention of Variceal Rebleeding: Stratifying Risk and Individualizing Care
Albillos A, Abraldes J, Ripoll C, Reiberger T, Augustin S, Salerno F, Moreau R, Garcia-Tsao G. Prevention of Variceal Rebleeding: Stratifying Risk and Individualizing Care. 2016, 311-316. DOI: 10.1007/978-3-319-23018-4_31.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsStandard of careCombination therapyVariceal rebleedingVariceal ligationChild AChild B/C patientsChild B/CSecond-line therapyStandard combination therapyIndividual patient dataLow rebleedingVariceal bleedC patientsPortal hypertensionCirrhotic patientsLine therapyRisk stratificationTailor therapySuch therapyTherapyRebleedingPatientsPatient dataCarePrevention